Trial
NCT01032148
Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Roswell Park Cancer Institute
Collaborators
Novartis
Condition
Hodgkin's Lymphoma
Intervention
LBH589
Why stopped
lack of funding
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-01-12